Modification of immune response genes in various types of chronic lymphocytic leukemia

Genetic factors not only contribute to the development of chronic lymphocytic leukemia (CLL), but also can affect the nature of the pathological process. The study included 30 patients with CLL with indolent and progressive course of the disease. The patients were tested on prevalence of genetic pol...

Full description

Saved in:
Bibliographic Details
Published inUchenye zapiski (Sankt-Peterburgskiĭ gosudarstvennyĭ medit͡s︡inskiĭ universitet im. akad. I.P. Pavlova) Vol. 22; no. 1; pp. 21 - 24
Main Authors Nazarova, E. L., Shardakov, V. I., Dem’Yanova, V. T., Dokshina, I. A., Zotina, E. N.
Format Journal Article
LanguageEnglish
Russian
Published Academician I.P. Pavlov First St. Petersburg State Medical University 30.03.2015
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Genetic factors not only contribute to the development of chronic lymphocytic leukemia (CLL), but also can affect the nature of the pathological process. The study included 30 patients with CLL with indolent and progressive course of the disease. The patients were tested on prevalence of genetic polymorphisms in the genes of the innate immune response. Nineteen polymorphic loci in 14 genes were tested. It was found that with indolent course of CLL, mutant alleles of genes of tumor necrosis factor (TNF) (G-308A), Toll-like receptor (tolllike receptor - TLR) TLR9 (T-1237C) and TLR2 (Arg753Gln) (OR: 4.70, p = 0.05 and OR: 8.33, p = 0.03 and OR: 5.50, p = 0.05, respectively) statistically, were encountered much more frequently . In contrast, combination of normal homozygotes of these genes greatly increased the risk of progressive form of the disease. Presence of TNF gene polymorphism in the polymorphic locus -308, TLR2-753, TLR9-1237 can be associated with the nature of the clinical course of CLL to encourage use these markers as early additional diagnostic and prognostic criteria for unfavorable form of leukemic process in order to optimize chemotherapy.
ISSN:1607-4181
2541-8807
DOI:10.24884/1607-4181-2015-22-1-21-24